HEAL

– Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine – NanoFlu™ vaccine candidate induced significantly enhanced cell-mediated immune responses – NanoFlu was well-tolerated with a comparable safety profile Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious…

Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory […]